Key Development Milestone
Nanoscience Inc.
(`Nanoscience' or the `Group')
Key Development Milestone - Transition to Commercial Production
Nanoscience Inc., the specialist niche investor in emerging technologies with
strong commercial propositions from within the growing nanotechnology sector,
is pleased to announce that its wholly owned subsidiary, Toumaz Technology
Limited (`Toumaz'), has successfully developed and tested the first fully
integrated, single chip version, of its pioneering Sensium platform. As a
result of this significant development, Toumaz will be making available for the
first time its range of wireless remote patient monitoring applications to a
range of customers in both the healthcare and pharmaceutical sectors from the
beginning of March this year.
Since the Group's acquisition of Toumaz in November 2005, development of the
patented Advanced Mixed Signal (`AMx') technology into an integrated chip has
been critical for the commercialisation of the Sensium healthcare platform. The
significance of this development milestone is that it facilitates the volume
production of Toumaz's healthcare solution, thereby leading the way to
significant cost reduction and supply in commercial volumes.
The Sensium platform provides a whole solution to cover the last metre of
bio-data communication and connects the mobile patient via any network to his
or her healthcare provider. In addition, the directors of Nanoscience believe
that the complete system of intelligent body worn wireless sensors and
associated networking is delivered with significantly lower power consumption
than any currently available alternative solution thereby enabling longer
usage.
To date, Toumaz has been working extensively with more than 20 prospective
customers in both the USA and Europe on various product functionality trials
since the first Sensium non-integrated modules were produced in October of last
year. As a consequence of the trialing process and deepening commercial
interaction with potential customers, in January of this year Toumaz was
selected by a Fortune 100 company for inclusion in its official supplier list.
Chris Toumazou, Director, Nanoscience, commented:
"The large organisations we are engaged with in a range of industry sectors
view the integrated Sensium monitoring platform as a technological revolution
that will provide them with a range of opportunities around which to build
their own applications and services. With our integrated mobile patient
monitoring platform we bring together 3 key components:
* Firstly, we can gather real-time processed information from raw data that
is processed `on-chip' to intelligently extract key biosensor information
thereby providing real-time feedback to patients whilst enabling healthcare
providers to focus on the key issues and deliver care on a pre-emptive
basis.
* Secondly, our body worn sensors operate using our ultra-low power patented
AMx technology. This technology, coupled with low power radio and
intelligent information handling, results in an ultra-low power, body-worn
solution, enabling non-intrusive, continuous monitoring.
* Finally, our technology is now a complete end-to-end system providing the
low power radio link from the patient to the telecommunications network and
into the healthcare provider's database systems, offering new levels of
reassurance and enabling new service delivery models. The data collected by
our body worn Sensium chips is then filtered and processed by application
software and integrated into existing medical information systems, such as
those employing the worldwide HL7 standard. Accordingly, this completes the
end-to-end solution and the backbone of a revolutionary total patient care
package.
The integrated Sensium chip achieved all of its targeted accuracy and
performance parameters in functional testing only 18 months after its initial
specification, thereby signaling a breakthrough for a new generation of
low-cost, disposable, lifestyle and healthcare solutions, which have been
eagerly anticipated in the industry."
Guy Spelman, CEO Nanoscience, commented:
"The performance of the Toumaz team is to be congratulated. The single chip
Sensium announced today is the first in a planned family of low power sensor
interface systems currently being developed. The product roadmap over the next
18 months will deliver devices for the analysis of vital signs with even lower
power consumption and greater algorithmic efficiency, enabling longer product
life spans at even lower cost. This is a key step in our programme of
commercialisation."
-Ends-
Further information:
Richard Rose Nanoscience 07836 250 474
Andrew Tan Hansard Group 020 7245 1100
www.hansardgroup.co.uk
About Toumaz (www.toumaz.com)
Toumaz, the recent winner of the first prize at the fifth Oracle PartnerNetwork
(OPN) Innovation Awards for Europe, the Middle East and Africa is a developer
of advanced RF, analogue and mixed signal semiconductors. The focus of the
business is low power devices based on the company's proprietary AMx™ (Advanced
Mixed Signal) technology which addresses the needs of lower power consumption
for mobile and wirelessly connected systems.